Relevant bibliographies by topics / Precision cancer therapy

Academic literature on the topic 'Precision cancer therapy'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Precision cancer therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Precision cancer therapy"

1

Nalley, Catlin. "Precision Therapy in Lung Cancer." Oncology Times 42, no. 18 (September 20, 2020): 21. http://dx.doi.org/10.1097/01.cot.0000717748.60516.e7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Al-Janabi, Ismail. "Pharmacogenomics Driving Precision Cancer Medicine." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 3 (October 24, 2022): 48–63. http://dx.doi.org/10.54133/ajms.v3i.85.

Full text
Abstract:
Genetically-driven variations in the proteins associated with drug action and adverse effects can lead to a significant influence on cancer therapy. Cancer cells can accumulate a plethora of somatic mutations, beyond any existing germline variants, during their progression from normalcy to malignancy. The narrow therapeutic index that characterises cancer drugs and the life-threatening failure of therapy all point to the importance of considering the inclusion of pharmacogenomics when treating cancers. This narrative review discusses the application, merits and challenges of pharmacogenomics knowledge using a few representative examples. The adoption of a properly considered pharmacogenomic program during cancer treatments can be life-saving and rewarding.
APA, Harvard, Vancouver, ISO, and other styles
3

Wong, Ada Hang-Heng, and Chu-Xia Deng. "Precision Medicine for Personalized Cancer Therapy." International Journal of Biological Sciences 11, no. 12 (2015): 1410–12. http://dx.doi.org/10.7150/ijbs.14154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kato, Shumei, and Razelle Kurzrock. "An avatar for precision cancer therapy." Nature Biotechnology 36, no. 11 (November 2018): 1053–55. http://dx.doi.org/10.1038/nbt.4293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dummer, Reinhard. "Precision medicine and skin cancer therapy." Current Opinion in Oncology 26, no. 2 (March 2014): 182–83. http://dx.doi.org/10.1097/cco.0000000000000059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Thomas, Anish. "More precision in lung cancer therapy." Science Translational Medicine 7, no. 287 (May 13, 2015): 287ec79. http://dx.doi.org/10.1126/scitranslmed.aab3977.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schiff, Joshua P., Pedro C. Barata, Evan Y. Yu, and Petros Grivas. "Precision therapy in advanced urothelial cancer." Expert Review of Precision Medicine and Drug Development 4, no. 2 (March 4, 2019): 81–93. http://dx.doi.org/10.1080/23808993.2019.1582298.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sapiezynski, Justin, Oleh Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko. "Precision targeted therapy of ovarian cancer." Journal of Controlled Release 243 (December 2016): 250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Meiliana, Anna, Nurrani Mustika Dewi, and Andi Wijaya. "CAR T Cells: Precision Cancer Immunotherapy." Indonesian Biomedical Journal 10, no. 3 (December 28, 2018): 203–16. http://dx.doi.org/10.18585/inabj.v10i3.635.

Full text
Abstract:
BACKGROUND: Current cancer drugs and treatments are aiming at eradicating tumor cells, but often are more toxic then effective, killing also the normal cells and not selectively the tumor cells. There is good personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity, which called adoptive cell therapy (ACT). A review of the unique biology of T cell therapy and of recent clinical experience compels a reassessment of target antigens that traditionally have been viewed from the perspective of weaker immunotherapeutic modalities.CONTENT: Chimeric antigen receptors (CAR) are recombinant receptors which provide both antigen-binding and T cell-activating functions. Many kind of CARs has been reported for the past few years, targeting an array of cell surface tumor antigens. Their biologic functions have extremely changed following the introduction of tripartite receptors comprising a costimulatory domain, termed second-generation CARs. The combination of CARs with costimulatory ligands, chimeric costimulatory receptors, or cytokines can be done to further enhance T cell potency, specificity and safety. CARs reflects a new class of drugs with exciting potential for cancer immunotherapy.SUMMARY: CAR-T cells have been arising as a new modality for cancer immunotherapy because of their potent efficacy against terminal cancers. They are known to exert higher efficacy than monoclonal antibodies and antibodydrug conjugates, and act via mechanisms distinct from T cell receptor-engineered T cells. These cells are constructed by transducing genes encoding fusion proteins of cancer antigen-recognizing single-chain Fv linked to intracellular signaling domains of T cell receptors.KEYWORDS: chimeric antigen receptor, CAR T cells, adoptive cell therapy, ACT, T cell receptor, TCR, cancer, immunotherapy
APA, Harvard, Vancouver, ISO, and other styles
10

Henscheid, Nick, Eric Clarkson, Kyle J. Myers, and Harrison H. Barrett. "Physiological random processes in precision cancer therapy." PLOS ONE 13, no. 6 (June 29, 2018): e0199823. http://dx.doi.org/10.1371/journal.pone.0199823.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Precision cancer therapy"

1

Mooney, Marie R. "Precision Medicine Approaches to Integrating Genomics with Cancer Therapy| Applications in Glioblastoma and Lymphoma." Thesis, Van Andel Research Institute, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10275288.

Full text
Abstract:

The word "cancer" rarely stands alone, usually prefaced with its anatomical location: lung cancer, prostate cancer, brain cancer. With the advancement of high-throughput omics approaches, specific oncogenic events are reorganizing the landscape of cancer classification, at once creating commonalities between cancers arising in diverse anatomical locations and dividing organ-centric classifications of cancer into a multitude of subtypes. The term "precision medicine" postulates that these new, data-driven groupings based on molecular characterization are the key to making rational therapeutic choices.

The majority of this dissertation addresses the disconnect between extensive molecular characterization and poor cancer therapy outcomes for patients with glioblastoma multiforme (GBM). Despite clear evidence that hyperproduction of the ligand for PDGFR (platelet-derived growth factor receptor α) is sufficient to generate GBM of the proneural subtype, anti-PDGFRα therapeutics have proven disappointing in clinical trials. Cell adaptation contributes to therapeutic escape. In GBM, proneural tumor cells adopt transcriptional profiles of the mesenchymal subtype. The interconversion between the proneural and mesenchymal transcriptional classes within a tumor population presents both a challenge and an opportunity for therapeutic approaches. The proneural subtype has a proliferation phenotype and presents druggable targets such as PDGFRα. The mesenchymal subtype presents an invasive phenotype, but the targets are more challenging to drug. The typical screening for combination therapies that synergize to induce cell death is not as advantageous here, where the disease management is expected to include cytostatic drugs that act on two different aspects of the phenotype: proneurally mediated proliferation and mesenchymally mediated invasion. This work examines the applicability of a combination approach against a proneural target, PDGFRα, and mesenchymal targets in the STAT3 (signal transducer and activator of transcription 3) pathway, in the context of a proneural model of GBM.

The work is concluded with collection of work applying precision medicine in other disease contexts, most notably canine lymphoma.

APA, Harvard, Vancouver, ISO, and other styles
2

Jacobson, Timothy. "A Trans-Dimensional View of Drug Resistance Evolution in Multiple Myeloma Patients." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6099.

Full text
Abstract:
Multiple Myeloma (MM) is a treatable, yet incurable, malignancy of bone marrowplasma cells. This cancer affects many patients and many succumb to relapse of tumor burden despite a large number of available chemotherapeutic agents developed for therapy. This is because MM tumors are heterogeneous and receive protection from therapeutic agents by the microenvironment and other mechanisms including homologous MM-MM aggregation. Therefore, therapy failure and frequent patient relapse is due to the evolution of drug resistance, not a lack of available drugs. To analyze and understand this problem, the evolution of drug resistance has been explored and presented herein. We seek to describe the methods through which MM cells become resistant to therapy, and how this resistance evolves throughout a patient’s treatment history. We achieve this in five steps. First we review the patient’s clinical history, including treatments and changes in tumor burden. Second, we trace the evolutionary tree of sub-clones within the tumor burden using standard of care fluorescence in situ hybridization (FISH). Thirdly, immunohistochemistry slides are stained and aligned to quantify the level of environmental protection received by surrounding cells and plasma in the bone marrow microenvironment (coined environment mediated drug resistance score [EMDR]). The fourth analysis type is produced through a novel 384-well plate ex vivo chemosensitivity assay to quantify sensitivity of primary MM cells to chemotherapeutic agents and extrapolate these findings to 90-day clinical response predictions. In addition to direct clinical application in the choice of best treatment, this tool was also used to study changes in sensitivity of patient tumors to other drugs, and it was observed that, upon relapse, in addition to developing resistance to the current line of therapy, tumors become cross-resistant to agents that they were never exposed to. Finally, MM-MM homologous aggregation is quantified to assess the level of drug resistance contributed by clustering of patient tumor cells, which causes upregulation of Bcl-2 expression and other resistance mechanisms1. The findings of such experimentation improve comprehension of the driving factors that contribute to drug resistance evolution on a personalized treatment basis. The aforementioned factors all contribute in varying degrees for unique patient cases, seven of which are presented in depth for this project. In summary: Environmental protection plays a critical initial role in drug resistance, which is followed by increase in tumor genetic heterogeneity as a result of mutations and drug-induced Darwinian selection. Eventually, environment-independent drug resistant subpopulations emerge, allowing the tumor to spread to unexplored areas of the bone marrow while maintaining inherited drug resistant phenotype2. It is our hope that these findings will help in shifting perspective regarding optimal management of MM by finding new therapeutic procedures that address all aspects of drug resistance to minimize chance of relapse and improve quality of life for patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Mansinhos, Inês Filipa Paixão. "Detection of new actionable mutations in lung cancer precision therapy." Master's thesis, 2017. http://hdl.handle.net/10316/82998.

Full text
Abstract:
Dissertação de Mestrado em Bioquímica apresentada à Faculdade de Ciências e Tecnologia
O cancro de pulmão é a causa mais comum de morte por cancro, em todo o mundo, em ambos os sexos. Cerca de 80% a 85% dos casos de cancro de pulmão são pacientes com cancro de pulmão de não pequenas células (CPNPC), sendo os restantes 15% -20% cancro de pulmão de pequenas células (CPPC). O CPNPC é dividido em três grupos: adenocarcinoma, carcinoma de células escamosas e carcinoma de células grandes. Entre eles, os casos de adenocarcinoma representam cerca de 40 a 50% dos pacientes com CPNPC. O prognóstico para CPNPC é baixo, com uma taxa de sobrevivência de cinco anos inferior a 20% sendo esta, ainda, pior para o CPPC, com uma taxa de sobrevivência de cinco anos inferior a 5%.Durante muito tempo, os tratamentos de primeira linha foram a cirurgia, a quimioterapia ou a radioterapia. No entanto, a descoberta de várias mutações drivers da carcinogénese em pacientes com CPNPC, especialmente em casos de adenocarcinoma, permitiu o desenvolvimento de tratamentos personalizados com base nessas alterações moleculares específicas. Deste modo, as mutações no EGFR (Recetor do Fator de Crescimento Epidérmico) representam até 15% dos adenocarcinomas e ocorrem principalmente no domínio tirosina quinase (TK) do gene. Mais de 80% dessas mutações consistem em deleções in-frame no exão 19 e na mutação pontual L858R no exão 21. Tais mutações induzem uma ativação constitutiva do EGFR, tornando-se um potencial alvo terapêutico. Assim, os pacientes portadores de mutações no EGFR podem beneficiar de um tratamento específico de primeira linha, mais especificamente, de inibidores de TK (TKI) que, de forma competitiva, inibem a fixação da adenosina trifosfato (ATP) ao local de ligação catalítica do domínio TK. Foram, também, propostos outros driver biomarcadores em cancro de pulmão podendo, alguns deles, fornecer informações adicionais para a tomada de decisões clínicas.Desta forma, o objetivo principal deste projeto foi avaliar mutações noutros alvos potencialmente acionáveis - MET e ERBB2 - em pacientes com adenocarcinoma, através da sequenciação de Sanger, e desenvolver um ensaio multiplex de PCR em tempo real, para uma rápida e sensível avaliação do estado mutacional em tecido e em plasma. Este ensaio também dará a oportunidade de monitorizar a evolução do estado mutacional no plasma durante o tratamento, para a predição de recidiva e controlo do aparecimento de clones com mutações de resistência.Do total de 172 amostras, 161 (88,9%) foram classificadas como negativas para alterações nos exões 18, 19, 20 e 21 do EGFR, enquanto 19 (11,1%) foram classificadas como positivas. No total das 19 alterações encontradas no EGFR, 73,7% foram deleções no exão 19 e 21% relataram a mutação Leu858Arg. Um caso de uma alteração T790M foi, também, encontrado num paciente. Numa frequência mais baixa, um caso Leu861Gln também foi relatado. No gene MET, as mesmas 172 amostras foram, igualmente, analisadas. Destas, 9 amostras (5,2%) apresentaram alterações no gene, incluindo 2 variantes intrónicas, 2 mutações indel e 5 mutações pontuais, no exão 14. As alterações no ERBB2 foram analisadas em 69 amostras, tendo sido detetado um caso de inserção de 12 bases no exão 20.Este trabalho permitiu concluir que uma proporção importante de casos apresenta mutações no MET e ERBB2, sendo que tais pacientes poderiam ser tratados com fármacos aprovados para esses alvos.
Lung cancer is the most common cause of cancer death around the world, in both sex. About 80%–85% of lung cancer cases are non-small-cell lung cancer (NSCLC) patients, the remaining 15%–20% are small-cell lung cancer (SCLC). NSCLC is divided into three categories called: adenocarcinoma, squamous-cell carcinoma and large cell carcinoma. Among them, adenocarcinoma cases account for around 40-50% of NSCLC patients. The prognosis for NSCLC is low with a five-year survival rate of less than 20%, and is even worse for SCLC with a five-year survival rate of less than 5%.For a long time, the first-line treatments have been surgery, chemotherapy or radiotherapy. However, the discovery of several oncogenic driver mutations in patients with NSCLC, adenocarcinoma cases in particular, has allowed the development of personalized treatments based on these specific molecular alterations. Therefore, EGFR (epidermal growth factor receptor) mutations account for up to 15% of adenocarcinoma and primarily occurred in the tyrosine kinase (TK) domain of the gene. More than 80% of these mutations consist of in-frame deletions in exon 19 and the L858R point mutation in exon 21. Such mutations induced a constitutive activation of EGFR, making it a potential therapeutic target. Thus, EGFR-mutated patients can benefit from a specific first-line treatment specifically the TK inhibitors (TKI) that competitively inhibits fixation of adenosine triphosphate (ATP) in the catalytic binding site of TK domain. Other driver biomarkers in lung cancer have also been proposed and some of them might provide additional information for clinical decision-making. In this way, the main goal of this project was to evaluate mutations in other potentially actionable targets – MET and ERBB2– in patients with adenocarcinoma by Sanger sequencing and to develop a Real Time PCR multiplex assay for rapid sensitive assessment of mutation profile in tissue and plasma. This assay, will also give the opportunity to monitor the evolution of mutational status in the plasma during the treatment for the prediction of relapse and control the appearance of clones with resistance mutations.Of the total of 172 samples, 161 (88.9%) were classified as negative for alterations in exons 18, 19, 20 and 21 of EGFR, whereas 19 samples (11.1%) were classified as positive. In total of the 19 alterations in EGFR, 73.7% were deletions in exon 19 and 21% was related to Leu858Arg mutation. A case of a T790M alteration was also founded in a patient. At a lower frequency, a case of a Leu861Gln was also reported. In MET gene, the same 172 samples were, also, analyzed. Of these, 9 samples (5.2%) harbored alterations in MET gene, including 2 intronic variants, 2 indel mutations and 5 pontual mutations in exon 14. ERBB2 alterations were analyzed in 69 samples and one case of an insertion of 12 bases in exon 20 were detected.This work allowed us to conclude that an important proportion of cases harbors mutations in MET and ERBB2 and these patients could potentially be treated with approved drugs for these targets.
APA, Harvard, Vancouver, ISO, and other styles
4

Perera-Bel, Julia. "Guiding Cancer Therapy: Evidence-driven Reporting of Genomic Data." Doctoral thesis, 2018. http://hdl.handle.net/11858/00-1735-0000-002E-E511-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Martins, Catarina Fortunato. "Laser ablation of tumour cells via precision nanomedicine." Master's thesis, 2021. http://hdl.handle.net/10362/125768.

Full text
Abstract:
O cancro é uma doença complexa que afeta a multiplicação das células, sendo uma das principais causas de mortalidade em todo o mundo. Embora existam vários tipos de terapias oncológicas disponíveis, a mais usada para tratar o cancro é a cirurgia e a quimioterapia, ambas com efeitos secundários indesejados e limitados ao tipo de cancro. A nano medicina é o campo da ciência e da tecnologia, que utiliza sistemas à escala nano para o diagnóstico, tratamento ou prevenção de uma doença. As nanopartículas de ouro (AuNPs) são utilizadas em diversas aplicações, devido às suas propriedades como a biocompatibilidade, relação superfície-volume elevada e facilidade de funcionalização. As AuNPs são usadas principalmente em fototerapia, uma vez que a radiação irá desencadear uma conversão foto térmica, destruindo as células cancerígenas e por sua vez reduzindo o volume do tumor. A terapia genética tem surgido como uma excelente abordagem para a terapia oncológica, utilizando oncogenes ou supressores de tumores. c-MYC é um dos oncogenes mais estudados, cuja expressão é desregulamentada em vários cancros, estando envolvido na proliferação, crescimento e metabolismo celular. Deste modo, foi sugerida uma terapia combinada, explorando as AuNPs como sistemas de “theranostic”, entre a terapia genética e fototerapia. Os resultados obtidos da sinergia de ambas as terapias puderam indicar que a hipertermia aumenta a permeabilidade celular, aumentando assim o silenciamento genético do c-MYC em quase 70%.
Cancer is defined as a complex set of diseases that affect the multiplication of cells, being one of the leading causes of mortality worldwide. Although several types of cancer therapies are available, the most used to treat cancer are surgery and chemotherapy, both with several side effects and limited to certain types of cancer. Nanomedicine is the sci-ence and technology field that uses nanoscale systems to diagnose, treat, or prevent a disease. Gold nanoparticles (AuNPs) are highly used in biomedical applications due to their physical-chemical properties like biocompatibility, high surface-area-to-volume ra-tio, and ease of functionalization. AuNPs are mainly used in photothermal therapy, since the radiation will trigger a thermal photo conversion, destroying cancer cells thus reduc-ing the tumour volume. Gene therapy has emerged as an excellent approach to cancer therapy, using genes to treat a disease using oncogenes or tumour suppressors. c-MYC is an oncogene widely studied, whose expression is deregulated in various cancers, being involved in cell proliferation, growth, and metabolism. Thus, it was suggested a combi-natory therapy, exploring the AuNPs as "theranostic" systems, between gene therapy and photothermal therapy. The results achieved of the synergy of both therapies indicate that hyperthermia enhances the cell permeability, thus increasing the gene silencing of the c-MYC by almost 70%.
APA, Harvard, Vancouver, ISO, and other styles
6

Marques, Lúcia Deodata António Martins. "Cancer therapy : a focus on gut microbiota." Master's thesis, 2019. http://hdl.handle.net/10451/43238.

Full text
Abstract:
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2019
O cancro é uma doença com um grande impacto em todo o mundo, contribuindo de forma significativa para a mortalidade e a morbidade. Apesar da disponibilidade de vários tratamentos e o aparecimento de novas terapêuticas, este ainda é uma das principais causas de morte. O tratamento desta doença consiste num equilíbrio frágil entre a eficácia e os efeitos colaterais, sendo que alguns tratamentos podem ser responsáveis por uma toxicidade considerável, comprometendo a qualidade de vida dos doentes e reduzindo a intensidade de dose, o que em última instância pode comprometer o resultado. Esta revisão tem como objetivo recolher informação sobre a associação entre a terapêutica oncológica e microbiota intestinal. Não só a microbiota intestinal poderá trazer esperança para áreas como prevenção, diagnóstico precoce e prognóstico do cancro, mas também ter o intuito de otimizar a terapêutica oncológica, melhorando o perfil de toxicidade, aumentando a eficácia do tratamento e até mesmo levando ao desenvolvimento de novos tratamentos. A microbiota intestinal também poderia explicar parcialmente a resistência à terapêutica em alguns doentes, bem como as diferenças entre as respostas intra e interpessoal do hospedeiro, evidenciando a magnitude que a caracterização e a manipulação do microbioma poderia adicionar à terapêutica individualizada de cada doente. Em conclusão, a modulação da microbiota intestinal, através da suplementação com determinados probióticos, prebióticos ou ambos, dieta ou mesmo através do transplante de microbiota fecal, poderá tornar possível a personalização da microbiota intestinal dos doentes, a fim de melhorar as suas respostas e alcançar melhores resultados no tratamento do cancro. Apesar de grandes feitos terem sido alcançados nesta área, uma maior consciencialização, pesquisa e validação da transposição de dados são necessárias para aplicar com segurança a medicina de precisão relacionada com a microbiota na prática clínica diária.
Cancer is responsible for a major burden of disease worldwide, contributing for both mortality and morbidity. Despite the availability of several cancer treatments and the arise of novel therapies, cancer is still a major cause of death. Cancer treatment is always a fragile balance between efficacy and side effects, with some treatments being able to cause significant side effects that compromise patients’ quality of life and, ultimately, reduce dose intensity, which could compromise the outcome. This review aims to gather information about the association between cancer therapy and gut microbiota. Not only gut microbiota could bring hope to areas like prevention, early diagnostic and prognostic of cancer, but could also improve cancer treatment, by ameliorating side effects, enhancing treatment efficacy and hopefully lead to the development of new therapies. Gut microbiota could also partially explain therapy resistance in some patients and the differences between intra and interpersonal host responses, evidencing the magnitude that microbiome characterization and manipulation could add to individual care. Modulation of gut microbiota, through antibiotics, supplementation with certain prebiotics, probiotics or both, diet or even through fecal microbiota transplant, could customize the patients’ microbiota with the objective of improving their outcomes and reducing side effects. Even though great steps have been made, further awareness, research and validation of data transposition are necessary to safely apply microbiota precision medicine into daily clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
7

Tillner, Falk. "Das Bildgeführte Präzisionsbestrahlungsgerät für Kleintiere (SAIGRT): von der Entwicklung bis zur Praxisreife." 2019. https://tud.qucosa.de/id/qucosa%3A70604.

Full text
Abstract:
Das entwickelte Bildgeführte Präzisionsbestrahlungsgerät für Kleintiere (engl. Small Animal Image-Guided Radiation Therapy – SAIGRT) dient der schnellen, hochauflösenden Röntgenbildgebung und präzisen, konformalen Bestrahlung von Kleintieren im Rahmen präklinischer in-vivo Experimente für die translationale Krebsforschung. Speziell programmierte Softwares zur Gerätesteuerung sowie zur Bildkorrektur- und Bildrekonstruktion auf dem zentralen leistungsfähigen Arbeitsplatz-PC stellen alle Gerätefunktionen zur Verfügung und ermöglichen durch automatisierte Abläufe und intuitive grafische Nutzeroberflächen eine einfache, sichere Bedienung. Für die Bestrahlungsplanung wird eine vollwertige, aus der humanen klinischen Strahlentherapie adaptierte 3D-Bestrahlungsplanungssoftware eingesetzt, die etablierte Werkzeuge für den Transfer und die Koregistrierung multimodaler Bilddaten, die Konturierung und Segmentierung von Zielvolumina und Risikoorganen sowie die Erstellung und Validierung von Bestrahlungsplänen enthält. Die resultierende Dosisverteilung wird darin basierend auf dem individuellen CT-Datensatz des Versuchstieres und einem auf das SAIGRT angepassten Maschinenmodell mittels eines Monte-Carlo-Algorithmus exakt und realitätsnah simuliert. Durch geometrische Kalibrierungen und vielfältige Basisdatenmessungen für die Bildgebung und Bestrahlung im Rahmen der Gerätekommissionierung ist eine Zielgenauigkeit von ca. ±0,1 mm mit hoher geometrischer Abbildungstreue und guter Bildqualität bei Bildgebungsdosen vergleichbar denen klinischer Radiografie- und CT-Geräte möglich. Die Dosisverteilung zur Bestrahlung der Versuchstiere spiegelt bei der definierten Strahlungsqualität größenskaliert die humane Strahlentherapie mit hochenergetischer Photonenstrahlung von klinischen Linearbeschleunigern wider. Ein umfassendes Qualitätssicherungsprogramm bestehend aus regelmäßiger Wartung und wiederkehrenden Konstanzprüfungen der Bildgebung und Bestrahlung sichert dauerhaft den technisch einwandfreien Zustand und die ordnungsgemäße Verfügbarkeit aller Gerätefunktionen in gleichbleibender Güte. Das SAIGRT ist somit nachweislich geeignet, bildgeführte Bestrahlungen mit einem Ablauf analog dem einer modernen klinischen Strahlentherapie am Menschen in präklinischen in-vivo Experimenten präzise an Kleintieren zu applizieren. Es leistet dadurch einen essentiellen Beitrag zur translationalen Krebsforschung in Dresden, indem die klinische Situation realistischer modelliert und so potenziell die Übertragbarkeit der Ergebnisse auf Krebspatienten verbessert werden kann.
The Small Animal Image-Guided Radiation Therapy (SAIGRT) platform facilitates fast, high resolution X-ray imaging and precise, conformal irradiation of small animals in preclinical in-vivo experiments for translational cancer research. Dedicated software for device control as well as image correction and reconstruction on a central high performance PC provide all device functions and allow simple and safe operation by automated procedures and intuitive graphical user interfaces. A fully 3D treatment planning software adapted from human clinical radiation therapy is used for treatment planning, containing established tools and methods for the transfer and registration of multimodality imaging data, contouring and segmentation of target volumes and organs at risk as well as creation and evaluation of treatment plans. Based on an individual CT scan of the small animal and a machine model adapted for the SAIGRT, the resulting dose distribution is simulated by a Monte-Carlo algorithm in a precise and realistic manner. Geometrical calibrations as well as manifold basic data measurements for X-ray imaging and irradiation during commissioning resulted in a targeting and imaging accuracy of about ±0.1 mm, a correct representation of imaging geometry and a good image quality with imaging doses comparable with those of clinical radiography and CT systems. Dose distribution of the defined beam quality used for irradiation of small animals reflects a downsized human radiation therapy using high energy photon beams of clinical linear accelerators. A comprehensive quality assurance program comprising regular maintenance and periodic constancy tests of X-ray imaging and irradiation ensures permanent technically perfect condition and proper availability of all implemented functions in a stable high quality. The SAIGRT platform is feasible for image-guided irradiations precisely applied to small animals in preclinical in-vivo experiments using a workflow of modern human radiation oncology. Thus, it significantly contributes to translational cancer research by more realistic modelling the clinical situation and potentially brings the results closer to their clinical implementation.
APA, Harvard, Vancouver, ISO, and other styles
8

Ferreira, Mariana Catarina Andrade. "Imunoterapia do cancro." Master's thesis, 2019. http://hdl.handle.net/10284/7703.

Full text
Abstract:
O cancro surge como uma das doenças mais prevalentes, incidentes e mortais da atualidade, sendo os mais incidentes, o cancro do pulmão, mama, próstata e colorretal. Em Portugal, particularmente na região Norte, surge ainda o cancro da tiroide e estômago no género feminino. O sistema imunológico tem a função de manter a homeostasia do organismo, através de uma resposta coletiva e coordenada de células, tecidos, órgãos e moléculas responsáveis pela eliminação de ameaças ao bom funcionamento do corpo humano. No entanto, algumas patologias podem afetar a eficácia do sistema imunológico, como as neoplasias que surgem pela acumulação de mutações nas células que o organismo por qualquer motivo não consegue reparar nem eliminar do ciclo celular. Fatores como a inflamação, o microambiente tumoral, as próprias células que constituem o sistema imune, a predisposição para fatores genéticos e a exposição a determinados agentes carcinogénicos, potenciam o aparecimento de neoplasias. Para isso, é necessário compreender o papel de cada um deles, para assim conseguir direcionar, otimizar e desenvolver terapêuticas mais eficazes. Neste sentido, surge uma nova forma de terapia, diferente das convencionais, com menos toxicidade e efeitos adversos, que utiliza as células do próprio organismo para combater a doença, a imunoterapia. Terapias como, Checkpoint Imunológico que envolve dois anticorpos monoclonais, Transferência Celular e Adotiva e Vacinas Tumorais, fazem parte desta inovação e apresentando já resultados muito promissores em alguns modelos tumorais. Por conseguinte, surge também o conceito de medicina de precisão onde é possível criar perfis específicos para um determinado doente, com um determinado tipo de cancro.
Cancer appears as one of the most prevalent, incidental and deadly diseases of the present time, being cancer of the lung, breast, prostate and colorectal the ones with more incidence. In Portugal, particularly in the North and in the female gender, there is also cancer of the thyroid and stomach. The immune system has the function of maintaining the body's homeostasis through a collective and coordinated response of cells, tissues, organs and molecules responsible for eliminating threats to the proper functioning of the human body. However, some pathologies may affect the effectiveness of the immune system, such as neoplasms which arise from the accumulation of mutations in cells that the body, for some reason, can not repair or eliminate from the cell cycle. Factors such as inflammation, tumor microenvironment, the cells that make up the immune system, predisposition to genetic factors and exposure to certain carcinogenic agents, potentiate the appearance of neoplasm. For this, it is necessary to understand the role of each of them, in order to be able to direct, optimize and develop more effective therapies. In this sense, a new form of therapy arises, different from the conventional ones, with less toxicity and adverse effects, that uses the organism’s cells to fight the disease, the immunotherapy. Therapies such as, Immunological Checkpoint involving two monoclonal antibodies, Cellular and Adoptive Transfer and Tumor Vaccines, are part of this innovation and nowadays it shows very promising results in some tumor models. Therefore, the concept of precision medicine also arises where it is possible to create specific profiles for a particular patient with a particular type of cancer.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Precision cancer therapy"

1

Von Hoff, Daniel D., and Haiyong Han, eds. Precision Medicine in Cancer Therapy. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hoff, Daniel D. Von, and Haiyong Han. Precision Medicine in Cancer Therapy. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hoff, Daniel D. Von, and Haiyong Han. Precision Medicine in Cancer Therapy. Springer International Publishing AG, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chick Chorioallantoic Membrane Model and Precision Cancer Therapy. Elsevier, 2019. http://dx.doi.org/10.1016/s1874-6047(19)x0003-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tamanoi, Fuyuhiko. Chick Chorioallantoic Membrane Model and Precision Cancer Therapy. Elsevier Science & Technology, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tamanoi, Fuyuhiko. Chick Chorioallantoic Membrane Model and Precision Cancer Therapy. Elsevier Science & Technology Books, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Giordano, Antonio, and Vincenzo Canzonieri. Gastric Cancer In The Precision Medicine Era: Diagnosis and Therapy. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Soares, Christiane Pienna, Zhi Ping (Gordon) Xu, Ângela Sousa, and Hernane Da Silva Barud, eds. Nanotechnology for Precision Cancer Therapy: Advances in gene therapy, immunotherapy, and 3D bioprinting. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-821-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fleck, Leonard M. Precision Medicine and Distributive Justice. Oxford University PressNew York, 2022. http://dx.doi.org/10.1093/oso/9780197647721.001.0001.

Full text
Abstract:
Abstract Wicked ethical problems have been generated by precision medicine due to both the wiliness of cancer and the fragmentation of health care financing in the United States. The wiliness of cancer has resulted in these targeted cancer therapies yielding only very marginal gains in life expectancy for most patients at very great cost, thereby threatening the just allocation of health care resources. As a life-threatening phenomenon, cancer is not morally special. Philosophers have high hopes for the utility of their theories of justice. However, metastatic cancer and costly precision medicines generate extremely complex problems of health care justice that none of these theories can address adequately. What is needed instead is a political conception of health care justice (following Rawls) and a fair and inclusive process of rational democratic deliberation governed by public reason. A basic assumption is that society has only limited health care resources to meet unlimited health care needs (generated by emerging medical technologies). The primary ethical and political virtue of rational democratic deliberation is that it allows citizens as citizens to fashion autonomously shared understandings of how to address fairly the complex problems of health care justice generated by precision medicine. Still, in a pluralistic world, ideally just outcomes are a moral and political impossibility. Wicked problems can metastasize if rationing decisions are made invisibly, in ways effectively hidden from those affected by those decisions. A fair and inclusive process of democratic deliberation makes wicked problems visible to public reason.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Precision cancer therapy"

1

Gatalica, Zoran, Rebecca Feldman, Semir Vranić, and David Spetzler. "Immunohistochemistry-Enabled Precision Medicine." In Precision Medicine in Cancer Therapy, 111–35. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, John K., and Saul J. Priceman. "Precision Medicine-Enabled Cancer Immunotherapy." In Precision Medicine in Cancer Therapy, 189–205. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roos, Alison, and Sara A. Byron. "Genomics-Enabled Precision Medicine for Cancer." In Precision Medicine in Cancer Therapy, 137–69. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hill, Addie, Rohan Gupta, Dan Zhao, Ritika Vankina, Idoroenyi Amanam, and Ravi Salgia. "Targeted Therapies in Non-small-Cell Lung Cancer." In Precision Medicine in Cancer Therapy, 3–43. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gately, Stephen. "Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients." In Precision Medicine in Cancer Therapy, 253–64. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schork, Nicholas J. "Artificial Intelligence and Personalized Medicine." In Precision Medicine in Cancer Therapy, 265–83. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sachdev, Jasgit C., Ana C. Sandoval, and Mohammad Jahanzeb. "Update on Precision Medicine in Breast Cancer." In Precision Medicine in Cancer Therapy, 45–80. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Demeure, Michael J. "The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers." In Precision Medicine in Cancer Therapy, 81–108. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pierobon, Mariaelena, Julie Wulfkuhle, Lance A. Liotta, and Emanuel F. Petricoin III. "Utilization of Proteomic Technologies for Precision Oncology Applications." In Precision Medicine in Cancer Therapy, 171–87. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Korn, Ronald L., Syed Rahmanuddin, and Erkut Borazanci. "Use of Precision Imaging in the Evaluation of Pancreas Cancer." In Precision Medicine in Cancer Therapy, 209–36. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Precision cancer therapy"

1

Kothari, Vishal, Wei Iris, Sunita Shankar, Shanker Kalyana-Sundaram, Lidong Wang, Linda W. Ma, Pankaj Vats, et al. "Abstract PR16: Targeting cancer-specific kinase dependency for precision therapy." In Abstracts: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities - May 17-20, 2013; Bellevue, WA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.pms-pr16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Xuefeng. "Abstract LB-222: Culturing cancer cells from liquid biopsies for precision cancer therapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-lb-222.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

D'Andrea, Alan D. "Abstract IA12: Targeting DNA repair in cancer therapy." In Abstracts: AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.pmccavuln16-ia12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ashworth, Alan. "Abstract IA14: Harnessing genetic dependencies in cancer therapy." In Abstracts: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities - May 17-20, 2013; Bellevue, WA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.pms-ia14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hwa, KuoYuan, and Kreeti Kajal. "Design for an in silico Platform of Precision Medicine on Cancer Therapy." In the 2018 5th International Conference. New York, New York, USA: ACM Press, 2018. http://dx.doi.org/10.1145/3301879.3301904.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Herman, Jacob A., Patrick J. Paddison, Jennifer DeLuca, and James Olson. "Abstract B27: Kinetochore-microtubule attachments as a precision therapy target." In Abstracts: AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; February 28 - March 2, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3125.cellcycle16-b27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sawyers, Charles L. "Abstract IA22: Reflections on precision medicine." In Abstracts: AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; June 13-16, 2015; Salt Lake City, UT. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.pmsclingen15-ia22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chantrill, Lorraine, Skye Simpson, Amber Johns, Mona Martyn-Smith, Angela Chou, Clare Watson, Adnan Nagrial, et al. "Abstract CT210: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-ct210.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Puca, Loredana, Wouter R. Karthaus, Dong Gao, John Wongvipat, Andrea Sboner, Marcello Gaudiano, Chantal Pauli, et al. "Abstract 3098: Epigenetic therapy to target neuroendocrine prostate cancer using precision medicine models." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3098.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ahmadi, Saba, Pattara Sukprasert, Rahulsimham Vegesna, Sanju Sinha, Natalie Artzi, Samir Khuller, Alejandro A. Schäffer, and Eytan Ruppin. "Abstract 2688: The landscape of precision cancer combination therapy: a single-cell perspective." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2688.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Precision cancer therapy"

1

Skelly, Andrea C., Roger Chou, Joseph R. Dettori, Erika D. Brodt, Andrea Diulio-Nakamura, Kim Mauer, Rongwei Fu, et al. Integrated and Comprehensive Pain Management Programs: Effectiveness and Harms. Agency for Healthcare Research and Quality (AHRQ), October 2021. http://dx.doi.org/10.23970/ahrqepccer251.

Full text
Abstract:
Objectives. To evaluate the effectiveness and harms of pain management programs that are based on the biopsychosocial model of care, particularly in the Medicare population. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, CINAHL®, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews) from 1989 to May 24, 2021; reference lists; and a Federal Register notice. Review methods. Given lack of consensus on terminology and program definition for pain management, we defined programs as integrated (based in and integrated with primary care) and comprehensive (referral based and separate from primary care) pain management programs (IPMPs and CPMPs). Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) comparing IPMPs and CPMPs with usual care or waitlist, physical activity, pharmacologic therapy, and psychological therapy in patients with complex acute/subacute pain or chronic nonactive cancer pain. Patients needed to have access to medication support/review, psychological support, and physical function support in programs. Meta-analyses were conducted to improve estimate precision. We classified the magnitude of effects as small, moderate, or large based on predefined criteria. Strength of evidence (SOE) was assessed for the primary outcomes of pain, function, and change in opioid use. Results. We included 57 RCTs; 8 evaluated IPMPs and 49 evaluated CPMPs. Compared with usual care or waitlist, IPMPs were associated with small improvements in pain in the short and intermediate term (SOE: low) and in function in the short term (SOE: moderate), but there were no clear differences at other time points. CPMPs were associated with small improvements in pain immediately postintervention (SOE: moderate) but no differences in the short, intermediate, and long term (SOE: low); for function, improvements were moderate immediately postintervention and in the short term; there were no differences in the intermediate or long term (SOE: low at all time points). CPMPs were associated with small to moderate improvements in function and pain versus pharmacologic treatment alone at multiple time frames (SOE: moderate for function intermediate term; low for pain and function at all other times), and with small improvements in function but no improvements in pain in the short term when compared with physical activity alone (SOE: moderate). There were no differences between CPMPs and psychological therapy alone at any time (SOE: low). Serious harms were not reported, although evidence on harms was insufficient. The mean age was 57 years across IPMP RCTs and 45 years across CPMP RCTs. None of the trials specifically enrolled Medicare beneficiaries. Evidence on factors related to program structure, delivery, coordination, and components that may impact outcomes is sparse and there was substantial variability across studies on these factors. Conclusions. IPMPs and CPMPs may provide small to moderate improvements in function and small improvements in pain in patients with chronic pain compared with usual care. Formal pain management programs have not been widely implemented in the United States for general populations or the Medicare population. To the extent that programs are tailored to patients’ needs, our findings are potentially applicable to the Medicare population. Programs that address a range of biopsychosocial aspects of pain, tailor components to patient need, and coordinate care may be of particular importance in this population.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Precision cancer therapy' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography